New approaches to overcoming bacterial resistance

Drugs of the Future

Volumn 34, Issue 2, 2009, Pages 127-136

  Fukuda, Y ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 [3 [(ETHYLAMINO)METHYL] 1 PYRROLIDINYL] 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 1 ETHYL 7 [3 (ETHYLAMINOMETHYL) 1 PYRROLIDINYL] 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AFN 1252; AM 1954; AM 7359; AMOXICILLIN PLUS CLAVULANIC ACID; BEDEROCIN; BETA LACTAMASE INHIBITOR; CBR 2092; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; CLINAFLOXACIN; GARENOXACIN; GATIFLOXACIN; ICLAPRIM; LINEZOLID; MCB 3837; NORFLOXACIN; NXL 104; OXAQUIN; OXAZOLIDINONE DERIVATIVE; PLEUROMUTILIN; QUINOLONE DERIVATIVE; RADEZOLID; REP 8839; RETAPAMULIN; SB 264128; SITAFLOXACIN; TIAMULIN; TIGECYCLINE; TOREZOLID; TR 701; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CHEMICAL MODIFICATION; DRUG STRUCTURE; GRAM POSITIVE INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; REVIEW; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 76649130202     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.02.1313642     Document Type: Review

References (50)

1. Pallin, D.J., Egan, D.J., Pelletier, A.J., Espinota, J.A., Hooper, D.C., Camargo, C.A. Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008, 51(3): 291-8.
2. Tong, S.Y., McDonald, M.I., Holt, D.C., Currie, B.J. Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in indigenous populations. Clin Infect Dis 2008, 46(12): 1871-8.
3. Izumida, M., Nagai, M., Ohta, A. et al. Epidemics of drug-resistant bacterial infections observed in infectious disease surveillance in Japan, 2001- 2005. J Epidemiol 2007,17(SuppL): S42-7.
4. Deshpande, L.M., Fritsche, T.R., Moet, G.J., Biedenbach, D.J., Jones, R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007, 58(2): 163-70.
5. Jansen, W.T., Verel, A., Beitsma, M., Verhoef, J., Milatovic, D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae. J Antimicrob Chemother 2006, 58(4): 873-7.
6. Lavilla, S., González-López, J.J., Sabaté, M. et al. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother 2008, 61(2): 291-5.
7. Cantón, R., Novais, A., Valverde, A., Machado, E., Peixe, L., Baquero, F., Coque, T. M. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008, 14(Suppl. 1): 144-53.
8. Bush, K. Extended-spectrum beta-lactamases in Nonh America, 1987- 2006. Clin Microbiol Infect 2008, 14(Suppl. 1): 134-43.
9. Tam, V.H., Gamez, E.A., Weston, J.S. et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin- tazobactam: Implications on the appropriateness of the resistance break-point. Clin Infect Dis 2008, 46(6): 862-7.
10. Nicasio, A.M., Kuti, J.L., Nicolau, D.P. The current state of multidrug-resistont gram-negative bacilli in North America. Pharmacotherapy 2008, 28(2): 235-49.
11. Payne, D.J., Gwynn, M.N., Holmes, D.J., Pompliano, D.L. Drags for bad bugs; confronting the challenges of antibacterial discovery. Nat Rev Drug Discovery 2007, 6(1): 29-40.
12. Chan, P.F., Holmes, D.J., Payne, D.J. Findings the gems using genomic discovery: Antibacterial drug discovery strategies - The successes and the challenges. Drug Discov Today 2004,1(4): 519-27.
13. Wang, J., Soisson, S.M., Young, K. et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441(7091): 358-61.
14. Karlowsky, J.A., Laing, N.M., Baudry, T., Kaplan, N., Vaughan, D., Hoban, D.J., Zhanel, G.G. In vitro activity of API-1252, a novel Fabl inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 2007, 51(4): 1580-1.
15. Critchley, I.A., Young, C.L., Stone, K.C., Ochsner, U.A., Guiles, J., Tarasow, T., Janjic, N. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother 2005, 49(10): 4247-52.
16. Noel, G.J., Bush, K., Bagchi, P., Ianus, J., Strauss, R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus cef tazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008, 46(5): 647-55.
17. Van Landuyt, H.W., Pyckavet, M., Lambert, A.M. Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates. J Antimicrob Chemother 1981, 7(1): 65-70.
18. Bassetti, M., Righi, E., Viscoli, C. Novel beta-lactam antibiotics and inhibitor combinations. Expert Opin Investig Drugs 2008, 17(3): 285-96.
19. O'Connor, J.J., Baughn, C.O., Pilote, R.R., Alpaugh, W.C., Linkenheimer, W.H., Maplesden, D.C. Tiamulin in the feed for the prevention of swine dysentery and growth promotion of growing pigs. J Anim Sci 1979, 49(4): 933-8.
20. Brooks, G., Burgess, W., Colthurst, D. et al. Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates. Bioorg Med Chem 2001, 9(5): 1221-31.
21. Rittenhouse, S., Biswas, S., Broskey, J. et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006, 50(11): 3882-5.
22. Takadoi, M., Sato, T., Fukuda, Y. Synthesis of C-20 substituted mutilin. 234th ACS Natl Meet (Aug 19-23, Boston) 2007, Abst ORGN166.
23. Takadoi, M., Sato, T., Fukuda, Y. Synthesis and antibacterial activity of novel C-12 substituted mutilins. 47th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst F1-1696.
24. Brickner, S.J., Hutchinson, D.K., Barbachyn, M.R. et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996, 39(3): 673-9.
25. Tsiodras, S., Gold, H.S., Sakoulas, G. et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358(9277): 207-8.
26. Auckland, C., Teare, L., Cooke, F. et al. Linezolid-reslstant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002, 50(5): 743-6.
27. Jones, R.N., Della-Latta, P., Lee, L.V., Biedenbach, D.J. Linezolid-resistant Enterococcus faecium Isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002, 42(2): 137-9.
28. Herrero, I.A., Issa, N.C., Patel, R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002, 346(11): 867-9.
29. Potoski, B.A., Mangino, J.E., Goff, D.A. Clinical failures of linezolid and implications for the clinical microbiology laboratory. Emerging Infect Dis 2002, 8(12): 1519-20.
30. Rahim, S., Pillai, S.K., Gotd, H.S., Venkataraman, L., lnglima, K., Press, R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003, 36(11): E146-8.
31. Choi, S., Son, T., Lee, T., Rhee, J. TR-701 (DA-7218) is significantly more potent than linezolid in skin and soft tissue models of infection. 47th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst F1-1691.
32. Lawrence, L., Danese, P., Devito, J., Franceschi, F., Sutcliffe, J. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother 2008, 52(5): 1653-62.
33. Fukuda, Y., Hammond, M.L. (Merck & Co. Inc.; Kyorin Seiyaku KK). Bicyclic[3.1.0]hexane containing oxazolidinone antibiotic and derivatives thereof. WO 03027083. Another group independently reported similar azabicyclo[3.1.0]hexane derivatives, see: Renslo, A.R., Jaishankar, P., Venkatachalam, R., Hackbarth C., Lopez, S., Patel, D.V., Cordeev, M.F. Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones. J Med Chem 2005, 48(15): 5009-24.
34. Komine, X, Kojima, A., Asahina, Y., Saito, T., Takano, H., Shibue, T., Fukuda, Y. Synthesis and SAR studies of highly potent novel oxazolidinone antibacterials. J Med Chem 2008, 51(20): 6558-62.
35. Ebisu, H., Abuki, R., Takei, M., Fukuda, H. Novel oxazolidinones: Antibacterial activities against respiratory pathogens and drug-resistant Gram-positive bacteria. 46th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 27-30, San Francisco) 2006, Abst F1-966.
36. Gill, C.J., Abruzzo, G.K., Flattery, A.M., Misura, A.S., Bartizal, K., Hickey, EJ. In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrob Agents Chemother 2007, 51(9): 3434-6.
37. Overbye, K.M., Mordekhay, D. AM-7359 - A novel oxazolidinone with low resistance potential and potent activity against drug resistant pathogens. J Chemother 2007, 19(3): 249-55.
38. Hirai, K., Ito, A., Abe, Y., Suzue, S., Irikura, T., lnoue, M., Mitsuhashi, S. Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother 1981, 19(1): 188-9.
39. Hosaka, M., Yasue, T., Fukuda, H., Tomizawa, H., Aoyama, H., Hirai, K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 1992, 36(10): 2108-17.
40. Domagala, J.M., Heifetz, C.L., Mich, T.F., Nichols, J.B. 1-Ethyl-7-[3-[(ethylamino)methyl]-l-pyrrolidinyl]-6,8-difluoro-l, 4-dihydro-3-quinolinecarboxylic acid. New quinolone antibacterial with potent Gram-positive activity. J Med Chem 1986, 29(4): 445-8.
41. Sanchez, J.P., Domagala, J.M., Hagen, S.E., Heifetz, C.L., Hutt, M.P., Nichols, J.B., Trehan, A.K. Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J Med Chem 1988, 31(5): 983-91.
42. 1 for the quinolone antibacterials. J Med Chem 1988, 31(5): 991-1001.
43. Kawakami, K., Namba, K., Tanaka, M., Matsuhashi, N., Sato, K., Takemura, M. Antimycobacterial activities of novel levofloxocin analogues. Antimicrob Agents Chemther 2000, 44(8): 2126-9.
44. Asahina, Y., Takei, M., Kimura, T., Fukuda, Y. Synthesis and antibacterial activity of novel pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid derivatives carrying the 3-cyclopropylaminomethyl-4-substituted-l- pyrrolldinyl group as a C-10 substituent. J Med Chem 2008, 51(11): 3238-49.
45. Sader, H.S., Mallick, R., Kuznik, A., Fritsche, T.R., Jones, R.N. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections, lnt J Antimicrob Agents 2007, 30(6): 514-20.
46. Stein, G.E., Craig, W.A. Tigecycline: A critical analysis. Clin Infect Dis 2006, 43(4): 518-24.
47. Kohlhoff, S.A., Sharma, R. Iclaprim. Expert Opin Investig Drugs 2007,16: 1441-8.
48. Gray, C.P., Cappi, M.W., Frimodt-Moller, N. Efficacy studies of MCB 3837, a dual-action antibiotic, in experimental infections in mice. 45th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, DC) 2005, Abst F-513.
49. Du, Q., Doyle, T.B., Duncan, L., Robertson, G.T.,. Lynch, A.S. In vitro microbiology profiling of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic. 47th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst F1-2103.
50. Krause, K.M., Difuntorum, S., Blais, J., Turner, S.D., Marquess, D. TD-1792, a new antibiotic with improved in vitro activity. 47th lntersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 17-20, Chicago) 2007, Abst E-1626.